In vivo and in vitro effect of sirolimus on insulin secretion

Transplantation

Volumn 83, Issue 5, 2007, Pages 532-538

  Marcelli Tourvieille, Sophie ^a   Hubert, Thomas ^a   Moerman, Ericka ^a   Gmyr, Valéry ^a   Kerr Conte, Julie ^a   Nunes, Bertrand ^a   Dherbomez, Michèle ^a   Vandewalle, Brigitte ^a   Pattou, François ^a   Vantyghem, Marie Christine ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Apoptosis; Insulin secretion; Islet transplantation; Sirolimus; Type 1 diabetes

Indexed keywords

ADENOSINE TRIPHOSPHATE; INSULIN; RAPAMYCIN;

ADULT; ANALYTIC METHOD; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL CULTURE; CLINICAL PRACTICE; CONTROLLED STUDY; DOSE RESPONSE; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESPONSE; NONHUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL; SWINE;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; BLOOD GLUCOSE; CELLS, CULTURED; DNA; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; ISLETS OF LANGERHANS; MODELS, ANIMAL; SIROLIMUS; SWINE; SWINE, MINIATURE;

EID: 33947325503     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000255679.81792.dd     Document Type: Article

References (30)

1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 27: 230.
2. Shapiro AM, Lakey JR, Paty BW, et al. Strategic opportunities in clinical islet transplantation. Transplantation 2005; 79: 1304.
3. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060.
4. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293: 830.
5. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001; 72: 1181.
6. Fabian MC, Lakey JR, Rajotte RV, et al. The efficacy and toxicity of rapamycin in murine islet transplantation. In vitro and in vivo studies. Transplantation 1993; 56: 1137.
7. Kneteman NM, Lakey JR, Wagner T, et al. The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients. Transplantation 1996; 61: 1206.
8. Bell E, Cao X, Moibi JA, et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 2003; 52: 2731.
9. Paty BW, Harmon JS, Marsh CL, et al. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and wistar rat islets. Transplantation 2002; 73: 353.
10. Lopez-Talavera JC, Garcia-Ocaña A, Sipula I, et al. Hepatocyte growth factor gene therapy for pancreatic islets in diabetes: reducing in the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation. Endocrinology 2004; 145: 467.
11. Hui H, Khoury N, Zhao X, et al. Adenovirus-mediated XIAP gene transfer reverses the negative effects of immunosuppressive drugs on insulin secretion and cell viability of isolated human islets. Diabetes 2005; 54: 424.
12. Kerr-conte J, Pattou F, Xia Y, et al. Simple dithizone-stained multilayer test for selection of density gradient before human islet mass purification. Transplant Proc 1994; 26: 3413.
13. Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. Diabetes 1988; 37: 413.
14. Ricordi C, Gray DW, Hering BJ, et al. Islet isolation assessment in man and large animals. Acta Diabetol 1990; 27: 185.
15. Vandewalle B, Douillard C, Kerr Conte J, et al. Human pancreatic islet quality control: easy assessment of metabolic functions. Exp Clin Endocrinol Diabetes 1999; 107: 214.
16. Lukowiak B, Vandewalle B, Riachy R, et al. Identification and purification of functional human beta-cells by a new specific zinc-fluorescent probe. J Histochem Cytochem 2001; 49: 519.
17. Sheehan D, Hrapchak B. Theory and practice of histotechnology, 2nd ed. Ohio, Battelle Press, 1980, p 189.
18. Desai NM, Goss JA, Deng S, et al. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity. Transplantation 2003; 15: 1623.
19. Shapiro AM, Gallant HL, Hao EG, et al. The portal immunosuppressive storm: relevance to islet transplantation. Ther Drug Monit 2005; 27: 35.
20. Haruta T, Uno T, Kawahara J, et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteosomal degradation of insulin receptor substrate-1. Mol Endocrinol 2000; 14: 783.
21. Berg CE, Lavan BE, Rondinone CM. Rapamycin partially prevents insulin resistance induced by chronic insulin treatment. Biochem Biophys Res Commun 2002; 293: 1021.
22. Zhang N, Su D, Qu S, et al. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes 2006; 55: 2429.
23. Bussiere CT, Lakey JR, Shapiro AM, et al. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 2006; 49: 2341.
24. Mc Daniel ML, Marshall CA, Pappan Kl, et al. Metabolic and autocrine regulation of mammalian target of rapamycin by pancreatic beta-cells. Diabetes 2002; 51: 2877.
25. Muthukkumar S, Ramesh TM, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 1995; 60: 264.
26. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 27: 6680.
27. Hosoi H, Dilling MB, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999; 15: 886.
28. Shi Y, Frankel A, Radvanyi LG, et al. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995; 1: 1982.
29. Woltman AM, de Fijter JW, Kamerling SW, et al. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 2001; 98: 174.
30. Shah SA, Potter MW, Ricciardi R, et al. FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation. J Surg Res 2001; 97: 123.